These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 9408860)

  • 1. Bayesian population pharmacokinetic and pharmacodynamic analyses using mixture models.
    Rosner GL; Müller P
    J Pharmacokinet Biopharm; 1997 Apr; 25(2):209-33. PubMed ID: 9408860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mixed Bayesian networks: a mixture of Gaussian distributions.
    Chevrolat JP; Rutigliano F; Golmard JL
    Methods Inf Med; 1994 Dec; 33(5):535-42. PubMed ID: 7869953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics/pharmacodynamics modeling: parametric and nonparametric methods.
    Jelliffe R; Schumitzky A; Van Guilder M
    Ther Drug Monit; 2000 Jun; 22(3):354-65. PubMed ID: 10850405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.
    Bustad A; Terziivanov D; Leary R; Port R; Schumitzky A; Jelliffe R
    Clin Pharmacokinet; 2006; 45(4):365-83. PubMed ID: 16584284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bayesian nonparametric population models: formulation and comparison with likelihood approaches.
    Wakefield J; Walker S
    J Pharmacokinet Biopharm; 1997 Apr; 25(2):235-53. PubMed ID: 9408861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nonparametric density estimation applied to population pharmacokinetics.
    Claret L; Iliadis A
    Math Biosci; 1996 Apr; 133(1):51-68. PubMed ID: 8868572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diazepam pharamacokinetics from preclinical to phase I using a Bayesian population physiologically based pharmacokinetic model with informative prior distributions in WinBUGS.
    Gueorguieva I; Aarons L; Rowland M
    J Pharmacokinet Pharmacodyn; 2006 Oct; 33(5):571-94. PubMed ID: 16810558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.
    Neely MN; van Guilder MG; Yamada WM; Schumitzky A; Jelliffe RW
    Ther Drug Monit; 2012 Aug; 34(4):467-76. PubMed ID: 22722776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical methods for population pharmacokinetic modelling.
    Racine-Poon A; Wakefield J
    Stat Methods Med Res; 1998 Mar; 7(1):63-84. PubMed ID: 9533262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients.
    Triggs EJ; Charles BG; Contin M; Martinelli P; Cortelli P; Riva R; Albani F; Baruzzi A
    Eur J Clin Pharmacol; 1996; 51(1):59-67. PubMed ID: 8880053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PFIM 4.0, an extended R program for design evaluation and optimization in nonlinear mixed-effect models.
    Dumont C; Lestini G; Le Nagard H; Mentré F; Comets E; Nguyen TT;
    Comput Methods Programs Biomed; 2018 Mar; 156():217-229. PubMed ID: 29428073
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A menu-driven software package of Bayesian nonparametric (and parametric) mixed models for regression analysis and density estimation.
    Karabatsos G
    Behav Res Methods; 2017 Feb; 49(1):335-362. PubMed ID: 26956682
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Smooth nonparametric maximum likelihood estimation for population pharmacokinetics, with application to quinidine.
    Davidian M; Gallant AR
    J Pharmacokinet Biopharm; 1992 Oct; 20(5):529-56. PubMed ID: 1287201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two general methods for population pharmacokinetic modeling: non-parametric adaptive grid and non-parametric Bayesian.
    Tatarinova T; Neely M; Bartroff J; van Guilder M; Yamada W; Bayard D; Jelliffe R; Leary R; Chubatiuk A; Schumitzky A
    J Pharmacokinet Pharmacodyn; 2013 Apr; 40(2):189-99. PubMed ID: 23404393
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.
    Mandema JW; Verotta D; Sheiner LB
    J Pharmacokinet Biopharm; 1992 Oct; 20(5):511-28. PubMed ID: 1287200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the nonparametric estimation method in NONMEM VI.
    Savic RM; Kjellsson MC; Karlsson MO
    Eur J Pharm Sci; 2009 Apr; 37(1):27-35. PubMed ID: 19159684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adaptive control methods for the dose individualisation of anticancer agents.
    Rousseau A; Marquet P; Debord J; Sabot C; Lachâtre G
    Clin Pharmacokinet; 2000 Apr; 38(4):315-53. PubMed ID: 10803455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved designs for dose escalation studies using pharmacokinetic measurements.
    Piantadosi S; Liu G
    Stat Med; 1996 Aug; 15(15):1605-18. PubMed ID: 8858785
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bayesian design criteria: computation, comparison, and application to a pharmacokinetic and a pharmacodynamic model.
    Merlé Y; Mentré F
    J Pharmacokinet Biopharm; 1995 Feb; 23(1):101-25. PubMed ID: 8576840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bayesian nonparametric estimation of continuous monotone functions with applications to dose-response analysis.
    Bornkamp B; Ickstadt K
    Biometrics; 2009 Mar; 65(1):198-205. PubMed ID: 18510655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.